What Is a Carryover Effect in a Crossover Trial?

What Happens When the First Treatment Still Affects the Second Treatment Period?

Imagine a crossover trial comparing two interventions, A and B. Participants receive A during the first period, stop treatment, and then begin B.

But what if A continues to influence their responses after B has started?

The researcher may observe an outcome during the B period that reflects not only B but also the lingering consequences of A. The result could make B appear more effective, less effective, or more similar to A than it would otherwise appear.

This problem is called carryover. It is one of the most consequential threats to the interpretation of crossover trials because it challenges the assumption that outcomes under successive treatments can be compared meaningfully.

Carryover Occurs When an Earlier Treatment Influences a Later Treatment Period

How Carryover Arises and Why It Matters for Causal Interpretation

What Exactly Carries Over Between Treatment Periods?

Carryover concerns the continuing influence of a previous intervention after the participant has moved into another treatment period.

The earlier intervention itself may remain active, or its consequences may persist even after the intervention has ended.

For example, a drug may remain biologically active after administration stops. Alternatively, an intervention may produce a physiological adaptation that continues after the drug has been eliminated.

In behavioral or educational research, participants may retain strategies, knowledge, habits, or expectations acquired during the earlier condition.

The defining feature is that exposure history affects the outcome observed under the subsequent treatment.

How Does Carryover Appear in an AB/BA Crossover Trial?

Consider a randomized two-treatment, two-period crossover trial. Participants are assigned to either AB or BA.

In the first period, participants have not yet received the other study treatment. In the second period, their responses may depend on both the current intervention and the previous one.

If the residual effects of A and B differ, the observed treatment contrast may vary according to the assigned sequence.

This is why randomized sequence allocation is necessary but not sufficient. Randomization determines who receives each order; it does not remove the biological or behavioral consequences of earlier exposure.

What Is the Difference Between Carryover and a Period Effect?

A period effect is an outcome difference associated with the measurement period rather than the current treatment.

Suppose participants perform better during the second period because they are more familiar with the testing environment. If this improvement occurs similarly regardless of the treatment sequence, it may be represented as a common period effect.

Carryover is different because the later response depends specifically on the treatment administered previously.

Both may occur in the same trial. Researchers must also consider treatment-by-period interactions, where the current treatment effect changes across periods for reasons that may not be reducible to a simple additive carryover term.

The broader problem of order-related influences in experiments includes these distinct mechanisms.

Can Carryover Be Positive or Negative?

Yes. Carryover may increase or decrease the outcome measured during a later period.

Suppose treatment A improves a participant's performance and some benefit persists during the B period. B may then appear more effective than it would have appeared without prior A exposure.

Alternatively, if A causes lingering fatigue or another unfavorable effect, performance under B may be worse.

The direction of bias depends on the treatment effects, residual effects, sequence allocation, and outcome scale.

Carryover is sometimes described as tending to reduce observed treatment differences in conventional crossover trials. That may occur under particular assumptions, but it is not a universal mathematical consequence. Differential carryover can bias an estimated contrast in either direction.

What Is First-Order Carryover?

First-order carryover refers to a model in which the outcome during a treatment period may depend on the treatment administered immediately before it.

For example, in a three-period sequence ABC, a first-order carryover model considers the influence of A on the B period and B on the C period.

It does not ordinarily include a direct residual influence of A on C after the intervening B period.

That restriction is an assumption about the persistence of earlier effects, not a guarantee that more distant exposure histories are irrelevant.

If an intervention produces effects that last across several subsequent periods, a first-order model may be inadequate.

Structured counterbalancing arrangements can balance selected immediate predecessor relationships, but they do not automatically remove the carryover effects themselves.

How Can Carryover Bias the Estimated Treatment Effect?

Consider a simplified two-period crossover model with additive treatment effects, a common period effect, and treatment-specific carryover affecting only the second period.

Let the direct treatment effects be represented by τ_A and τ_B, while λ_A and λ_B represent the residual effects of A and B.

For the AB sequence, the within-participant difference between the A and B periods includes the direct treatment contrast, the period effect, and residual A carryover.

For the BA sequence, the corresponding contrast includes the same direct treatment contrast, an oppositely signed period effect, and residual B carryover.

With equal sequence weighting, the common additive period effect cancels when the appropriately oriented contrasts are averaged.

The calculation illustrates why the direction and magnitude of bias depend on differential residual effects. It does not imply that carryover parameters can be reliably estimated from an ordinary two-period crossover dataset.

Indeed, the difficulty of separating direct treatment effects from treatment-specific carryover is a central reason for evaluating carryover plausibility before the trial.

Does Equal Carryover From Both Treatments Cancel?

Under the simplified balanced additive model, equal carryover parameters produce no differential carryover term in the estimated A − B contrast.

However, this result depends on the model and estimand. Equal residual effects do not establish that participants have returned to their original states, and carryover may interact with current treatment or measurement period.

Researchers should therefore avoid treating equal carryover as a general justification for ignoring exposure history.

Can a Washout Period Prevent Carryover?

A washout period is an interval between treatment periods intended to allow residual effects to diminish.

It can be useful when intervention effects are temporary and their duration can be reasonably established.

For example, a pharmacological crossover trial may consider elimination kinetics and the persistence of biological effects when determining the interval between treatments.

However, drug elimination and disappearance of treatment effects are not always equivalent. A biological response may persist after the administered substance is no longer present at an appreciable concentration.

In educational research, a waiting period cannot reliably eliminate knowledge acquired during an earlier intervention.

The appropriate question is therefore not simply how long participants should wait, but whether the residual influence of the first treatment is sufficiently negligible when the subsequent outcome is measured.

Determining an appropriate washout duration requires evidence about the intervention and outcome rather than an arbitrary interval.

Can Researchers Detect Carryover With a Statistical Test?

Statistical tests for carryover have been proposed, but their interpretation is difficult, particularly in conventional two-period crossover trials.

A nonsignificant test does not establish that carryover is absent. Limited statistical power may prevent detection of effects that are substantively important.

Furthermore, carryover parameters may be difficult to distinguish from sequence-related differences without additional assumptions.

Using a preliminary carryover test to decide whether to analyze both periods or only the first can introduce additional inferential problems.

The Cochrane Handbook identifies carryover as a principal concern when assessing bias in crossover trials and cautions against selecting first-period analyses on the basis of a preliminary carryover test.

How Can Carryover Be Investigated Without Relying on One Significance Test?

Researchers can examine several sources of evidence when evaluating possible carryover.

Prior studies may provide information about how long an intervention remains active. Pharmacokinetic or pharmacodynamic evidence may be relevant for medicines, while learning-retention evidence may be more appropriate for educational interventions.

Repeated measurements during washout may help characterize the return toward baseline when the outcome can be measured safely and meaningfully.

Descriptive outcomes by treatment, sequence, and period may also reveal patterns requiring explanation.

However, none of these observations automatically identifies the causal contribution of carryover. Their interpretation depends on measurement reliability, the underlying time course, and the assumptions of the design.

When residual effects remain plausible, researchers should examine how the conclusions depend on those assumptions and report the uncertainty transparently.

When Does Carryover Make a Crossover Trial Inappropriate?

Carryover becomes a fundamental design problem when earlier interventions produce persistent effects that cannot be sufficiently reduced before later outcome measurement.

This is particularly relevant to irreversible interventions, durable learning, permanent physiological changes, and outcomes that cannot meaningfully recur under different treatment conditions.

If the underlying condition also changes substantially across periods, distinguishing current treatment effects from exposure history may become even more difficult.

In such circumstances, the assumptions required for a conventional crossover trial may not be defensible.

A parallel-group trial may then provide a clearer comparison because participants are not required to receive both interventions sequentially.

How Residual Learning Can Distort a Crossover Comparison

The example does not establish that carryover occurred. The observed sequence pattern is compatible with several explanations, and the hypothetical means alone cannot isolate the residual effect of Tool A.

Its methodological lesson is that treatment responses may depend on prior exposure. Researchers should establish whether this dependency is part of the research question or a threat to the intended comparison.

Common Misconceptions About Carryover Effects

How to Address Carryover Before and During a Trial

The strongest response to carryover begins before data collection. Researchers should identify plausible mechanisms through which the first intervention might influence later outcomes.

Next, they should assess how long those effects may persist and whether the study can reasonably allow them to diminish before subsequent measurements.

For randomized crossover trials, the protocol should prespecify treatment sequences, washout rationale, outcome measurement timing, and the primary analysis.

The final report should present sufficient information about treatment periods and sequences for readers to evaluate the plausibility of carryover and the robustness of the interpretation.

Researchers should not treat the absence of a statistically significant carryover test as a substitute for substantive justification.

Before Assuming Carryover Is Negligible

Frequently Asked Questions About Carryover Effects

Carryover Makes Treatment History Part of the Outcome

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.